Artivion (AORT) Q2 FY26 earnings call

Artivion delivered solid Q2 FY26 results, marked by strong constant currency revenue growth and strategic milestones including the AMDS PMA approval and the Endospan acquisition. The company is focused on leveraging its expanded aortic arch portfolio and pipeline to drive long-term profitable growth, despite near-term impacts on EBITDA margin and free cash flow from integration and R&D investments. Management expressed confidence in achieving full-year guidance.